| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; and
Samuel C. Johnson Medical Research Building, Mayo Clinic Scottsdale, Scottsdale, AZ 85259
Dendritic cells (DC) are potent APCs. In this study, murine bone marrow-derived DC were transfected with RNA encoding the MUC1 Ag that is aberrantly overexpressed in human breast and other carcinomas. The MUC1 RNA-transfected DC exhibited cell surface expression of MUC1 and costimulatory molecules. After injection at the base of the tail, the transfected DC were detectable in inguinal lymph nodes by dual immunochemical staining. Vaccination of wild-type mice with MUC1 RNA-transfected DC induced anti-MUC1 immune responses against MUC1-positive MC38/MUC1, but not MUC1-negative, tumor cells. Mice immunized with the transfected DC were protected against challenge with MC38/MUC1 tumor cells. Furthermore, mice with established MC38/MUC1 tumors were eliminated after receiving the vaccination. CTLs isolated from mice immunized with the transfected DC exhibited specific cytolytic activity against MC38/MUC1 tumor cells. In contrast to these findings, there was little if any anti-MUC1 immunity induced with the transfected DC in MUC1 transgenic (MUC1.Tg) mice. However, coadministration of the transfected DC and IL-12 reversed the unresponsiveness to MUC1 Ag in MUC1.Tg mice and induced MUC1-specific immune responses. These findings demonstrate that vaccination of DC transfected with MUC1 RNA and IL-12 reverses tolerance to MUC1 and induces immunity against MUC1-positive tumors.
This article has been cited by other articles:
|
|
 |
|
  A. Landi, L. A. Babiuk, and S. van Drunen Littel-van den Hurk High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer J. Leukoc. Biol., October 1, 2007; 82(4): 849 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koido, E. Hara, S. Homma, M. Mitsunaga, A. Takahara, E. Nagasaki, H. Kawahara, M. Watanabe, Y. Toyama, S. Yanagisawa, et al. Synergistic Induction of Antigen-Specific CTL by Fusions of TLR-Stimulated Dendritic Cells and Heat-Stressed Tumor Cells J. Immunol., October 1, 2007; 179(7): 4874 - 4883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al. Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells J. Immunol., January 1, 2007; 178(1): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koido, E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, et al. Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer-Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells Clin. Cancer Res., November 1, 2005; 11(21): 7891 - 7900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Tacken, I. J. M. de Vries, K. Gijzen, B. Joosten, D. Wu, R. P. Rother, S. J. Faas, C. J. A. Punt, R. Torensma, G. J. Adema, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody Blood, August 15, 2005; 106(4): 1278 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Spadaro, E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W.-Z. Wei, P. Musiani, P.-L. Lollini, et al. Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity Clin. Cancer Res., March 1, 2005; 11(5): 1941 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cloosen, M. Thio, A. Vanclee, E. B. M. van Leeuwen, B. L. M. G. Senden-Gijsbers, E. B. H. Oving, W. T. V. Germeraad, and G. M. J. Bos Mucin-1 is expressed on dendritic cells, both in vitro and in vivo Int. Immunol., November 1, 2004; 16(11): 1561 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Avigan, B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. McDermott, T. Smith, et al. Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses Clin. Cancer Res., July 15, 2004; 10(14): 4699 - 4708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Heil, H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 Science, March 5, 2004; 303(5663): 1526 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, Y. Tang, H. Akbulut, D. Zelterman, P.-J. Linton, and A. B. Deisseroth An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells PNAS, December 9, 2003; 100(25): 15101 - 15106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, W. Li, S. Liang, D. Cai, M. P. Kieny, L. Jacob, A. Linnenbach, J. W. Abramczuk, H. Bender, K. Sproesser, et al. Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice J. Immunol., September 15, 2003; 171(6): 2922 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Hodge, D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom Vaccine Therapy of Established Tumors in the Absence of Autoimmunity Clin. Cancer Res., May 1, 2003; 9(5): 1837 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Chen, Y.-P. Lee, Y.-F. Chung, Y.-C. Shih, J.-P. Tsai, M.-H. Tao, and C.-C. Ting Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy Int. Immunol., March 1, 2003; 15(3): 427 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gong, S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12 Blood, April 1, 2002; 99(7): 2512 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bacci, C. Montagnoli, K. Perruccio, S. Bozza, R. Gaziano, L. Pitzurra, A. Velardi, C. F. d'Ostiani, J. E. Cutler, and L. Romani Dendritic Cells Pulsed with Fungal RNA Induce Protective Immunity to Candida albicans in Hematopoietic Transplantation J. Immunol., March 15, 2002; 168(6): 2904 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koido, Y. Tanaka, D. Chen, D. Kufe, and J. Gong The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice J. Immunol., March 1, 2002; 168(5): 2111 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wan, L. Lu, J. L. Bramson, S. Baral, Q. Zhu, A. Pilon, and K. Dayball Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN-{gamma}-Secreting, CD8+ CTL In Vivo J. Immunol., November 1, 2001; 167(9): 5027 - 5033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lee, F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, C. Gee, R. Lau, G. Jeffery, K. Margolin, et al. Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma J. Clin. Oncol., September 15, 2001; 19(18): 3836 - 3847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines Cancer Res., September 1, 2001; 61(17): 6445 - 6450. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
